Medimmune Limited

Humabs Biomed Sa

Anna DeMarco

Davide Corti

Antonio Lanzavecchia

Nicole Kallewaard-LeLay

Qing Zhu

Andy Q Yuan

Josephine Mary McAuliffe

Ebony Benjamin

Leslie Wachter

Frances Palmer-Hill

Barbara Guarino

Charles K Stover

Xiaodong Xiao

Martina Beltramello

Elisabetta Cameroni

Qun Wang

Meghan Pennini

Gilad Kaplan

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to02 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiellapneumoniae) and/or protects mice from a lethalchallenge. The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering thepneumoniae 02 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Anti-O2 antibodies and uses thereof

The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus.

Neutralizing anti-influenza A antibodies and uses thereof

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind toO2 and induce opsonophagocytic killing of(e.g.,) and/or protects mice from a lethalchallenge. The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering theO2 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.

Growing community of inventors

Bellinzona, Switzerland

Anna DeMarco